GoAI
Get started
Indivior Pharmaceuticals Inc logo

Indivior Pharmaceuticals Inc

INDV

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$36.87

−$0.91 · -2.41%

Aug 21, 4:00 PM ET

INDV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

71

Undervalued

Momentum

60

Neutral

Sentiment

55

Mixed

Risk resilience

70

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Joseph J. Ciaffoni
Listed since
Dec 29, 2014
Employees
833

Market position

Day range

Current $36.87

52-week range

Current $36.87

Open
$37.80
Previous close
$37.78
Volume
2.5M
1.21× average
Average volume
2.06M
Average daily volume
Market cap
4.6B USD
Beta
1.03
Market reference 1
50-day average
$39.5605
-6.80% below average
200-day average
$35.41
+4.12% above average

Earnings

EPS beat rate
82%
9 beats, 1 miss, 1 met estimate
Average EPS surprise
+46.03%
11 comparable reports
Latest EPS result
1.15
Estimate 0.87 · Beat by 32.34%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.220.880.530.19Q1 '25MetQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 0.32, estimate 0.32, surprise 0.00%, Met estimate. Q2 2025, reported Apr 24, 2025: actual 0.41, estimate 0.22, surprise +86.36%, Beat. Q3 2025, reported Jul 31, 2025: actual 0.51, estimate 0.26, surprise +96.15%, Beat. Q4 2025, reported Oct 30, 2025: actual 0.72, estimate 0.38, surprise +89.47%, Beat. Q1 2026, reported Feb 26, 2026: actual 0.82, estimate 0.65, surprise +26.15%, Beat. Q2 2026, reported Apr 30, 2026: actual 0.96, estimate 0.64, surprise +50.00%, Beat. Q3 2026, reported Aug 3, 2026: actual 1.15, estimate 0.869, surprise +32.34%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 1.06, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates372.32M323.48M274.65M225.81MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 299M USD, estimate 240.13M USD, surprise +24.51%, Beat. Q2 2025, reported Apr 24, 2025: actual 266M USD, estimate 242.3M USD, surprise +9.78%, Beat. Q3 2025, reported Jul 31, 2025: actual 302M USD, estimate 255.23M USD, surprise +18.32%, Beat. Q4 2025, reported Oct 30, 2025: actual 314M USD, estimate 306.22M USD, surprise +2.54%, Beat. Q1 2026, reported Feb 26, 2026: actual 358M USD, estimate 305.62M USD, surprise +17.14%, Beat. Q2 2026, reported Apr 30, 2026: actual 317M USD, estimate 272.84M USD, surprise +16.19%, Beat. Q3 2026, reported Aug 3, 2026: actual 343M USD, estimate 306.23M USD, surprise +12.01%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 329.35M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$48.00

30.19% upside
Past 12 months12-month forecastHigh $53.00Average $48.00Low $43.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy4100%
Hold00%
Sell00%
Strong sell00%

INDV news

zacks.com

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

Read source
gurufocus.com

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propos

Read source
businesswire.com

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals,…

Read source
zacks.com

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

Read source
gurufocus.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) PR Newsw

Read source
prnewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50…

Read source

INDV peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding INDV

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
289.95M
Weight
0.26%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
155.55M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
115.54M
Weight
0.14%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
112.17M
Weight
0.06%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
64.97M
Weight
0.15%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Invesco S&P SmallCap Momentum ETF logoInvesco S&P SmallCap Momentum ETFXSMO
Market value
63.62M
Weight
2.11%
AUM
3.04B USD
Expense ratio
0.36%
Price / 1D
$86.05+0.54%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
56.16M
Weight
0.06%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares S&P Small-Cap 600 Growth ETF logoiShares S&P Small-Cap 600 Growth ETFIJT
Market value
44.13M
Weight
0.52%
AUM
8.22B USD
Expense ratio
0.18%
Price / 1D
$173.9+0.61%

Continue in GoAI

Research INDV

research.disclaimer